Plague has killed millions of people during the past 25 centuries, and the disease reappeared in several countries during the 1990s. Consequently, plague was categorized as a re-emerging disease. Human plague outbreaks continue to be reported, including an outbreak of pneumonic plague in Madagascar in 20...
Tacconelli, E;
Mazzaferri, F;
Smet, A.M. de;
Bragantini, D;
Eggimann, P;
Huttner, B. D;
Kuijper, E. J;
Lucet, J. C;
Mutters, N. T;
Sanguinetti, M;
Schwaber, M. J;
Souli, M;
Torre-Cisneros, J;
Price, J. R;
Rodríguez-Bano, J.
The aim of these guidelines is to provide recommendations for decolonizing regimens targeting
multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings.
Methods: These evidence-based guidelines were produced after a systematic review of published studies
on decolonization intervention...
Gram-Negative Bacterial Infections/diagnosis,
Gram-Negative Bacterial Infections/prevention & control,
Gram-Negative Bacterial Infections/transmission,
Evidence-Informed Policy,
Enterobacteriaceae Infections/prevention & control,
Enterobacteriaceae Infections/transmission,
Enterobacteriaceae Infections/diagnosis,
Cephalosporin Resistance/drug effects,
Cephalosporins/therapeutic use,
Aminoglycosides/therapeutic use,
Fluoroquinolones/therapeutic use,
Fecal Microbiota Transplantation/instrumentation
Wedzicha, JA;
Calverley, PMA;
Albert, RK;
Anzueto, A;
Criner, GJ;
Hurst, JR;
Miravitlles, M;
Papi, A;
Rabe, KF;
Rigau, D;
Sliwinski, P;
Tonia, T;
Vestbo, J;
Wilson, KC;
Krishnan, JA.
This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.Comprehensive evidence syntheses were performed to summarise al...
Adrenergic beta-2 Receptor Agonists/therapeutic use,
Aminopyridines/therapeutic use,
Benzamides/therapeutic use,
Cyclopropanes/therapeutic use,
Fluoroquinolones/therapeutic use,
Macrolides/therapeutic use,
Muscarinic Antagonists/therapeutic use,
Phosphodiesterase 4 Inhibitors/therapeutic use,
Disease Progression,
Pulmonary Disease, Chronic Obstructive,
Pulmonary Disease, Chronic Obstructive/drug therapy,
Pulmonary Disease, Chronic Obstructive/physiopathology,
Secondary Prevention/standards,
Adrenergic beta-2 Receptor Agonists,
Aminopyridines,
Benzamides,
Cyclopropanes,
Fluoroquinolones,
Macrolides,
Muscarinic Antagonists,
Phosphodiesterase 4 Inhibitors
This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...
Tuberculosis, Multidrug-Resistant/diagnosis,
Antibiotics, Antitubercular/pharmacology,
Molecular Probe Techniques,
Microbial Sensitivity Tests,
Fluoroquinolones/therapeutic use,
Drug Resistance, Bacterial/genetics,
Genotype,
Mutation,
Tuberculosis, Multidrug-Resistant/genetics,
Mycobacterium tuberculosis/drug effects,
Mycobacterium tuberculosis/genetics
Community-acquired pneumonia is diagnosed by clinical features (e.g., cough, fever, pleuritic chest pain) and by lung
imaging, usually an infiltrate seen on chest radiography. Initial evaluation should determine the need for hospitalization versus outpatient management using validated mortality or severi...
Pneumonia/diagnostic imaging,
Pneumonia/therapy,
Respiratory Tract Diseases/diagnosis,
Ambulatory Care/organization & administration,
Blood Culture/instrumentation,
Macrolides/therapeutic use,
Doxycycline/therapeutic use,
Anti-Bacterial Agents/therapeutic use,
Fluoroquinolones/therapeutic use,
Intensive Care Units,
Healthcare-Associated Pneumonia/prevention & control
